ResApp Health (RAP) Stock Price, News & Analysis

Company Overview

ResApp Health Limited develops digital healthcare solutions to assist doctors and allow patients to diagnose and manage respiratory disease. The company offers ResAppDx, a smartphone-based acute respiratory disease diagnostic test for use in telehealth, emergency department, and primary care markets; and SleepCheck, a smartphone application that allows consumers to self-assess the risk of sleep apnoea. Its technology uses sound to diagnose respiratory diseases, including pneumonia, bronchiolitis, bronchitis, chronic obstructive pulmonary disease, and asthma. ResApp Health Limited has a joint development and pilot agreement with Medgate AG to integrate and test smartphone-based acute respiratory diagnostic test. The company was formerly known as Narhex Life Sciences Limited. ResApp Health Limited was incorporated in 2000 and is headquartered in Brisbane, Australia.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: 932,978 shs
• Average Volume: N/A
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Industry, Sector and Symbol

• Stock Exchange: ASX
• Sector: Medical
• Industry: Health Information Services
• Sub-Industry: N/A
• Current Symbol: ASX:RAP
• CUSIP: N/A
• CIK: N/A
• Web: www.resapphealth.com.au
• Phone: 61 7 3724 0035
• Fax: N/A
• Employees: 500
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: 5.64
• Current Ratio: 0.86
• Quick Ratio: 0.82

Sales & Book Value

• Annual Sales: $3.81 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: 28.33
• Book Value: A$0.00 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 859,697,024
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A